[Correspondence] Heteroresistance and clinical outcomes: much still to be understood–Authors’ reply

We read with great interest the Correspondence by Gabriele Maria Leanza and colleagues and appreciate this opportunity to comment on the authors’ insights. As the authors noted, escalation of care and admission to intermediate care unit or intensive care unit are confounded metrics. In our study, we identified an association between breakpoint crossing heteroresistance (BCHR) and admission to higher levels of care.1 Our interpretation of this finding is that when the BCHR phenotype was missed by clinical laboratories, patients in our cohort appeared to have a higher risk of admission to intermediate care unit or intensive care unit.